The UK MHRA has granted marketing authorization for nipocalimab (Imaavy) to treat generalized myasthenia gravis in adults and adolescents aged 12 years and older. The FcRn‑blocking therapy, administered intravenously every two weeks, expands targeted treatment options for patients inadequately controlled on standard care.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for nipocalimab (Imaavy) for adults and adolescents aged 12 years and older with generalized myasthenia gravis (gMG).
The intravenous FcRn-blocking therapy, administered every two weeks, offers a new targeted option for patients whose disease remains inadequately controlled despite standard care.
The authorization was issued on June 9, 2026, under the International Recognition Procedure (IRP), with Janssen-Cilag Limited as the marketing authorization holder.
Targeting Pathogenic IgG Autoantibodies
Generalized myasthenia gravis is driven by immunoglobulin G (IgG) autoantibodies that disrupt neuromuscular transmission, most commonly by targeting acetylcholine receptors. This leads to fluctuating muscle weakness and functional impairment affecting speech, swallowing, chewing, facial movement, and vision.
Nipocalimab, a monoclonal antibody against the neonatal Fc receptor (FcRn), reduces the recycling of IgG antibodies, thereby lowering circulating pathogenic autoantibodies and helping restore neuromuscular function.
Clinical Evidence Supporting Approval
The MHRA’s decision was supported by data from a pivotal study involving 153 adults with inadequately controlled gMG, supplemented by a supportive study in eight adolescents aged 12 to 17 years. Together, the studies demonstrated a benefit-risk profile that supported approval in both age groups.
Although the agency did not disclose detailed efficacy results in its authorization announcement, the available evidence met the standards required for regulatory approval.
Safety Profile and Monitoring
Adverse events reported in more than 10% of patients included elevated blood lipids, decreased albumin levels, muscle spasms, and peripheral edema affecting the hands, ankles, or feet. As with all newly authorized medicines, ongoing pharmacovigilance will continue through routine safety monitoring and the UK’s Yellow Card reporting system.
Expanding the FcRn Therapeutic Class
The authorization of nipocalimab adds to a growing class of FcRn-targeted therapies that are reshaping treatment for antibody-mediated autoimmune diseases.
By targeting the antibody-driven biology underlying disease, these therapies have expanded treatment options beyond traditional immunosuppressive approaches. The approval further highlights continued innovation in targeted immune therapies for neuromuscular disorders.
Regulatory Significance and Next Steps
The MHRA noted that generalized myasthenia gravis can significantly affect daily functioning and highlighted the importance of expanding treatment options for both adult and adolescent patients.
The Summary of Product Characteristics and Patient Information Leaflet are expected to be published on the MHRA Products website within seven days of approval.
With UK authorization secured, nipocalimab expands the growing range of targeted therapies available for generalized myasthenia gravis and provides an additional option for patients who continue to experience disease burden despite standard treatment.
Reference
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.